Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIb RCT of Sivelestat in Septic Coagulopathy
2025-523397-16-00Phase 2Authorised
- Sponsor
- Strasbourg University Hospital
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in sepsis-associated coagulopathy (SAC) and septic shock comparing Sivelestat with Placebo (2 arms). Primary endpoint: Primary: Change in plasma plasminogen levels at 24 hours. Planned start Jun 2026; status: authorised.
02
Drugs
sivelestat
03
Conditions
sepsis-associated coagulopathy (SAC)septic shock
Beyond the preview
Go deeper on 2025-523397-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523397-16-00.